May 10, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types regardless of prior therapy or disease ...
Regulated information — Inside information March 23, 2022, 9:00 PM ET March 24, 2022, 2:00 AM CET Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), ...
Regulated information — Inside information March 22, 2022 Breda, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from ...
VYVGART® (efgartigimod alfa-fcab) approved in the U.S. and Japan as the first-and-only neonatal Fc receptor (FcRn) blocker; U.S. commercial launch underway Topline results from Phase 3 bridging study of subcutaneous ...
January 3, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Copyright © 2015 - 2021 Lifecarenews.in
